The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SVRA | +18.49% | +264.66% | +29.53% | -53% |
| S&P | +14.84% | +96.04% | +14.41% | +182% |
Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Austin, TX.
The company released first-quarter earnings and said it had completed a phase 3 trial enrollment for its lead therapy.
The clinical-stage biopharmaceutical company focuses on therapies to treat rare respiratory diseases.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.07M | -7.2% |
| Market Cap | $394.07M | -29.2% |
| Market Cap / Employee | $6.68M | 0.0% |
| Employees | 59 | 59.5% |
| Net Income | -$30.40M | -36.7% |
| EBITDA | -$31.37M | -35.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $17.44M | -26.9% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $29.65M | 12.0% |
| Short Term Debt | $0.09M | -40.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -72.72% | -14.7% |
| Return On Invested Capital | -38.32% | 2.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$26.28M | -16.7% |
| Operating Free Cash Flow | -$26.26M | -16.7% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 3.63 | 2.63 | 2.79 | 2.66 | -41.72% |
| Price to Tangible Book Value | 3.85 | 2.79 | 2.96 | 2.87 | -42.68% |
| Enterprise Value to EBITDA | -26.84 | -15.82 | -16.07 | -12.01 | -56.67% |
| Return on Equity | -48.0% | -61.5% | -75.8% | -99.3% | 24.94% |
| Total Debt | $26.71M | $26.82M | $29.65M | $29.74M | 11.66% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
